Pregnancy registries
Antiretroviral pregnancy registry
Healthcare providers are encouraged to enroll pregnant women undergoing antiretroviral therapy (ART) in the Antiretroviral Pregnancy Registry, a voluntary, exposure-based, observational study designed to collect and evaluate data on the outcomes of pregnancy exposures to antiretroviral products. Patients can be registered via phone (1-800-258-4263), fax (1-800-800-1052), or by visiting https://www.apregistry.com.
To access a complete list of ART medications the registry monitors, visit https://www.apregistry.com.
Antiepileptic pregnancy registry
Pregnant female patients taking antiepileptic drugs are encouraged to enroll in the North American Antiepileptic Drug Pregnancy Registry, which actively collects information to help determine the safety of seizure medications during pregnancy. To register, call the toll-free number 1-888-233-2334.
For more information or a list of medications the registry monitors, visit https://www.aedpregnancyregistry.org/.
APO-FINGOLIMOD pregnancy registry
The APO-FINGOLIMOD Pregnancy Registry monitors fetal outcomes in women exposed to APO-FINGOLIMOD during pregnancy. If a patient becomes pregnant while taking APO-FINGOLIMOD, physicians are encouraged to report this by calling the registry at 1-800-667-4708.
Enhanced pharmacovigilance pregnancy active surveillance program (APO-TERIFLUNOMIDE)
Patients who have become pregnant or suspect they could be pregnant while taking APO-TERIFLUNOMIDE or up to two years after discontinuing APO-TERIFLUNOMIDE treatment should contact their healthcare provider. An Enhanced Pharmacovigilance Pregnancy Active Surveillance Program has been established to collect information on the effects of teriflunomide exposure during pregnancy. Physicians are encouraged to enroll pregnant women exposed to APO-TERIFLUNOMIDE in this program. Alternatively, pregnant women may enroll themselves by calling 1-800-667-4708 or 416-401-7780 and following prompts. Program details and educational materials are available here.